CERo Therapeutics closes $2.25M initial closing of Series E preferred stock financing, total $7M

CERO THERAPEUTICS HOLDINGS, INC.

Initial closing of 3,816 Series E preferred shares raised $2.25M gross proceeds on Oct 16, 2025.
Amendment to SPA added an additional buyer and increased initial closing by $500k; total remains $7M.
Series E preferred stock terms filed as Certificate of Designations on Oct 14, 2025.
Remaining $4.75M to be funded at additional closings under the Securities Purchase Agreement.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC.: Filed Certificate of Designations establishing Series E convertible preferred stock (effective 2025-10-14).

Change: charter amendment
Effective: 2025-10-14

Exact text from the filing

On October 14, 2025, the Company filed the Certificate of Designations of Rights and Preferences of the Series E Preferred Stock (the “Certificate of Designations”) for the purpose of designating and establishing the Company’s Series E convertible preferred stock, par value $0.0001 per share (the “Series E Preferred Stock”).

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-099560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.